← All trials
NCT05287399
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 2, 2022
- Primary completion
- Dec 20, 2022
- Completion date
- Mar 20, 2023
- First posted
- Mar 18, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 16
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gannex Pharma Co., Ltd.Lead sponsor
- Ascletis Pharmaceuticals Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.